The belief that newborns can develop opioid toxicity from breastfeeding is widely held but
supported by very little data. Based largely on a single, highly publicized case report (the …

Background Developmental physiology can alter pharmacotherapy in preterm populations.
Because of ethical and clinical constraints in studying this vulnerable age group …

Pharmacogenetics, the genetic influence on the interpersonal variability in drug response,
has enabled tailored pharmacotherapy and emerging 'personalized medicine.'Although …

Chemotherapy induced nausea and vomiting (CINV) is an adverse outcome commonly
experienced by patients receiving antineoplastic agents prior to hemopoietic stem cell …

Neonatal abstinence syndrome, or NAS, is a postnatal opioid withdrawal syndrome
occurring in 55% to 94% of neonates as a result of in utero exposure to opioids. It has …